Arneric SP, Holladay M, Williams M (2007)
Neuronal nicotinic receptors: a perspective on two decades of drug discovery research
Biochemical Pharmacology 74: 1092

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN (2006)
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship
Journal of Medicinal Chemistry 49: 4425

Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP (2005)
A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization
Journal of Neuroscience 25: 4396

Arneric SP, Holladay MW (2000)
Agonists and Antagonists of Nicotinic Acetylcholine Receptors
Handbook of Experimental Pharmacology 144: 419

Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch JM, Arneric SP, Gopalakrishnan M, Sullivan JP (1999)
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant
European Journal of Pharmacology 366: 301

Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M, Arneric SP (1998)
Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors
Science 279: 77

Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP (1998)
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization
Journal of Pharmacology & Experimental Therapeutics 285: 787

Decker MW, Curzon P, Holladay MW, Nikkel AL, Bitner RS, Bannon AW, Donnelly-Roberts D, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Williams M, Arneric SP (1998)
The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594
Journal de Physiologie (Paris) 92: 221

Decker MW, Bannon AW, Buckley MJ, Kim DJ, Holladay MW, Ryther KB, Lin NH, Wasicak JT, Williams M, Arneric SP (1998)
Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice
European Journal of Pharmacology 346: 23

Donnelly-Roberts D, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP (1998)
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization
Journal of Pharmacology & Experimental Therapeutics 285: 777

Holladay MW, Bai H, Li Y, Lin NH, Daanen JF, Ryther KB, Wasicak JT, Kincaid JF, He Y, Hettinger AM, Huang P, Anderson DJ, Bannon AW, Buckley MJ, Campbell JE, Donnelly-Roberts D, Gunther KL, Kim DJ, Kuntzweiler TA, Sullivan JP, Decker MW, Arneric SP (1998)
Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice
Bioorganic & Medicinal Chemistry Lett 8: 2797

Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts D, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP (1998)
Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors
Journal of Medicinal Chemistry 41: 407

Lin NH, Gunn DE, Li Y, He Y, Bai H, Ryther KB, Kuntzweiler T, Donnelly-Roberts D, Anderson DJ, Campbell JE, Sullivan JP, Arneric SP, Holladay MW (1998)
Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist
Bioorganic & Medicinal Chemistry Lett 8: 249

Molinari EJ, Delbono O, Messi ML, Renganathan M, Arneric SP, Sullivan JP, Gopalakrishnan M (1998)
Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands
European Journal of Pharmacology 347: 131

Prendergast MA, Jackson WJ, Terry AV, Jr., Decker MW, Arneric SP, Buccafusco JJ (1998)
Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys
Psychopharmacology (Berl) 136: 50

Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliott RL, Gopalakrishnan M, Holladay MW, Hui YH, Jackson WJ, Kim DJ, Marsh KC, O'Neill A, Prendergast MA, Ryther KB, Sullivan JP, Arneric SP (1997)
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo
Pharmacol Biochem Behav 57: 231

Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, Lin NH, Li Y, Daanen JF, Buccafusco JJ, Prendergast MA, Jackson WJ, Arneric SP (1997)
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys
Journal of Pharmacology & Experimental Therapeutics 283: 247

Lin NH, Gunn DE, Ryther KB, Garvey DS, Donnelly-Roberts D, Decker MW, Brioni JD, Buckley MJ, Rodrigues AD, Marsh KG, Anderson DJ, Buccafusco JJ, Prendergast MA, Sullivan JP, Williams M, Arneric SP, Holladay MW (1997)
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties
Journal of Medicinal Chemistry 40: 385

Puttfarcken PS, Manelli AM, Arneric SP, Donnelly-Roberts D (1997)
Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells
Journal of Neurochemistry 69: 930

Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin NH, Ryther KB, He Y, Holladay MW, Wonnacott S, Williams M, Arneric SP (1997)
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties
Journal of Pharmacology & Experimental Therapeutics 283: 235

Abreo MA, Lin NH, Garvey DS, Gunn DE, Hettinger AM, Wasicak JT, Pavlik PA, Martin YC, Donnelly-Roberts D, Anderson DJ, Sullivan JP, Williams M, Arneric SP, Holladay MW (1996)
Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors
Journal of Medicinal Chemistry 39: 817

Buisson B, Gopalakrishnan M, Arneric SP, Sullivan JP, Bertrand D (1996)
Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study
Journal of Neuroscience 16: 7880

Donnelly-Roberts D, Xue IC, Arneric SP, Sullivan JP (1996)
In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418
Brain Research 719: 36

Gopalakrishnan M, Monteggia LM, Anderson DJ, Molinari EJ, Piattoni-Kaplan M, Donnelly-Roberts D, Arneric SP, Sullivan JP (1996)
Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor
Journal of Pharmacology & Experimental Therapeutics 276: 289

Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger AM, Garvey DS, Wasicak JT, Holladay MW, Williams M, Arneric SP (1996)
A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand
Neuropharmacology 35: 725

Anderson DJ, Williams M, Pauly JR, Raszkiewicz JL, Campbell JE, Rotert G, Surber B, Thomas SB, Wasicak J, Arneric SP (1995)
Characterization of [3H]ABT-418: a novel cholinergic channel ligand
Journal of Pharmacology & Experimental Therapeutics 273: 1434

Arneric SP, Sullivan JP, Decker MW, Brioni JD, Bannon AW, Briggs CA, Donnelly-Roberts D, Radek RJ, Marsh KC, Kyncl J, Williams M, Buccafusco JJ (1995)
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties
Alzheimer Disease & Associated Disorders 9 Suppl 2: 50

Donnelly-Roberts D, Arneric SP, Sullivan JP (1995)
Functional modulation of human ganglionic-like neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists
Biochemical & Biophysical Research Communications 213: 657

Gopalakrishnan M, Buisson B, Touma E, Giordano T, Campbell JE, Hu IC, Donnelly-Roberts D, Arneric SP, Bertrand D, Sullivan JP (1995)
Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor
European Journal of Pharmacology 290: 237

Monteggia LM, Gopalakrishnan M, Touma E, Idler KB, Nash N, Arneric SP, Sullivan JP, Giordano T (1995)
Cloning and transient expression of genes encoding the human alpha 4 and beta 2 neuronal nicotinic acetylcholine receptor (nAChR) subunits
Gene 155: 189

Sullivan JP, Decker MW, Donnelly-Roberts D, Brioni JD, Bannon AW, Holladay MW, Anderson DJ, Briggs CA, Williams M, Arneric SP (1995)
Cholinergic channel activators: novel opportunities for the treatment of CNS disorders
Proc West Pharmacol Soc 38: 127

Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS (1994)
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization
Journal of Pharmacology & Experimental Therapeutics 270: 310

Garvey DS, Wasicak JT, Decker MW, Brioni JD, Buckley MJ, Sullivan JP, Carrera GM, Holladay MW, Arneric SP, Williams M (1994)
Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities
Journal of Medicinal Chemistry 37: 1055

Linville DG, Giacobini E, Arneric SP (1992)
Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow
Journal of Neuroscience Research 31: 573

Babu SR, Arneric SP, Dube SN, Somani SM (1991)
Poster: Effect of cholinesterase inhibitor and exercise on cholineacetyltransferase and acetylcholinesterase activities in rat brain regions
In: Cholinesterases: Structure, Function, Mechanism, Genetics, and Cell Biology (Massoulie J, Barnard EA, Chatonnet A, Bacou F, Doctor BP, Quinn DM) American Chemical Society, Washington, DC: 342